Volume 62

AUTHOR INDEX

ADIGUN, S.A. 51–56
ALON, U. 65–70, 431–433
ANDRÉN, L. 137–141
ARISTIMUNO, G. 307–309
AUG, F. 13–16

BACKMAN, U. 509–514
BANKS, R.A. 169–176
BARANOWSKI, R.L. 667–676
BARNES, P.J. 349–354, 661–665
BARTTER, F.C. 209–213
BAUER, J.H. 43–49
BEEVERS, D.G. 1–6
BEILIN, L.J. 169–176
BELLAVERE, F. 57–64
BELLMINGHAM, A.J. 479–488
BENHAMOU, J.-P. 273–277
BERANT, M. 431–433
BERNUAU, J. 273–277
BERTRAND, A. 13–16
BETTER, O.S. 65–70, 431–433
BEUERS, U. 341–342
BIANCHI, G.P. 683–686
BING, R.F. 361–366
BJÖRKNMA, M. 137–141
BJÖRNSÖN, Ö.G. 651–659
BLOOM, S.R. 651–659
BONJOUR, J.-P. 389–396, 503–508
BORG, K.O. 137–141
BOUHNISK, J. 355–360
BRADLEY, G.W. 311–319
BREWER, D.B. 495–502
BROOKS, C.S. 43–49
BROWN, M.J. 661–665
BRYSON, E.I. 595–604
BURKE, J.F. 553–556
BURSTON, D. 617–626

CAGLIERO, E. 239–242
CAMPBELL, I.L. 449–455
CATELEY, D.M. 595–604
CHADWICK, V.S. 651–659
CHAIMOVITZ, C. 65–70
CHARLESWORTH, J.A. 561–562
CHONG, C.K. 457–464
CHRISTOFIDES, N.D. 651–659

CLAUSER, E. 355–360
CLEGG, G. 489–494
CLEMENS, T.L. 427–429
CLOUGH, D.P. 51–56
COHEN, R.D. 411–420
CONDORELLI, M. 581–588
CONWAY, J. 51–56
CORTESE, C. 397–401
CORVOL, P. 355–360
CRAWFORD, P.A. 667–676
CREMONINI, C. 643–649
CROCKSON, A.P. 71–76
CRUIKSHANK, J.K. 1–6
CUMBERBATCH, M. 489–494
CUMMING, G. 541–547, 549–551

DANDONA, P. 177–181
DANIELSON, B.G. 509–514
DAVIDSON, L. 169–176
DE KEIZER, M.H. 435–437
DE LUCA, N. 581–588
DERKKX, F.H.M. 435–437
DOLLLERY, C.T. 349–354
DONDI, C. 683–686
DOWLING, R.H. 515–519
DRESLINSKI, G.R. 307–309

EDWARDS, R.H.T. 227–234
ENDRE, Z.H. 561–562
ERIKSON, L.S. 285–293
ESLER, M. 247–254
EVENWEL, R.T. 589–594
EWING, D.J. 57–64

FARR, M. 71–76
FELELSTRÖM, B. 509–514
FEVER, J. 521–528
FISHER, R. 279–283
FITZGERALD, G.A. 349–354
FLEISCH, H. 389–396, 503–508
FLETCHER, D.R. 651–659
FORBES, A.M. 479–488
FRAHER, L.J. 427–429
FRASER, R. 373–380
FRASER, T.R. 221–226
FROHLICH, E.D. 307–309

GALTON, D.J. 93–100
GARCIA DEL RIO, C. 143–149
GARDS, J. 355–360
GAUTHIER, C. 403–410
GLEASON, S.D. 471–477
GOLDBERG, A. 183–191
GOLDEN, M.H.N. 299–305
GOLDMAN, M.D. 7–11
GOLDSMITH, H.J. 479–488
GORDON, J.A. 235–238
GOZZI, C. 643–649
GREEN, J.R. 557–560
GRIFFITHS, J.R. 113–115
GÜLLNER, H.-G. 209–213
GUTTERIDGE, D.H. 221–226
GUYATT, A.R. 541–547

HAGENFELDT, L. 285–293
HALE, T. 311–319
HALLON, P.C. 17–19, 421–425
HAM, J.M. 279–283
HAMBURGER, R.K. 667–676
HANSSON, L. 137–141
HATTON, R. 51–56
HEATH, D.F. 83–91
HEFTI, E. 389–396
HELLQUIST, L.N.B. 449–455
HENDERSON, A.R. 337–339
HENDY, G.N. 381–387
HENRIKSEN, E. 605–609
HERITTING, G. 341–342
HESP, R. 595–604
HEYMA, P. 215–220
HILTON, P.J. 563–564
HIRSCH, F. 611–615
HOLBROOK, I.B. 83–91
HOLDSWORTH, G. 93–100, 125–129

HOLMGREN, K. 509–514
HOOD, B. 151–155
HOPWOOD, J.J. 193–201
HORSFIELD, K. 549–551
HOWARD, P. 255–259
HOWELL, J.B.L. 367–372
HUANG, W.-C. 573–579
HUGHES, I. 227–234
HUGHES, M.J. 143–149

IKEMOTO, F. 157–162
ILES, R.A. 411–420
IND, P.W. 661–665
IRVING, M.H. 83–91
Author Index

ISAACS, P.E.T.  203-207
IWAO, H.  157-162
JACKSON, A.A.  299-305
JACKSON, P.A.  101-107
JACOBS, A.  529-540
JAHOUR, P.  299-305
JENSEN, K.  605-609
JONES, R.B.  563-564
JOPLIN, G.F.  221-226
KARLBERG, B.E.  35-41
KAWASHIMA, S.  295-297
KEELING, P.W.N.  109-111
KIM, Y.S.  203-207
KNIEP, W.  341-342
KNUDSEN, L.  605-609
KOHN, E.M.  239-242
KONDO, K.  565-566
KOK, W.  549-551
KRAEGEN, E.W.  561-562
KROELEN, B.  329-336
KURTSMAN, N.A.  667-676
LACHER, J.W.  235-238
LAGER, L.  131-136
LAKATUA, D.J.  209-213
LAMBE, A.T.  27-33
LANGLEY, F.  549-551
LARKINS, R.G.  215-220
LASSEN, N.A.  567-572
LAWRENCE, G.M.  495-502
LEE, M.R.  439-448
LENTZE, M.J.  557-560
LEUNG, F.Y.  337-339
LEWIN, I.G.  381-387
LEWIS, B.  397-401
LIEBAU, G.  465-469
LINDSTEDT, G.  137-141
LIVESAY, J.H.  373-380
LIUNGHALL, S.  509-514
LUCZ, P.  677-682
LUFF, N.  595-604
LYNN, K.L.  21-26
MACDONALD, G.J.  561-562
MANLOVE, L.  479-488
MARIS, D.  367-372
MARCHESINI, G.  683-686
MARSHALL, R.D.  21-26
MASENI, A.  119-123
MATON, P.N.  515-519
MATTHEWS, D.M.  617-626
MATTIAS, I.  151-155
MCCOLL, K.E.L.  183-191
MCÉVOY, M.  279-283
MCKENNA, F.  489-494
MEANO, C.I.  163-167
MENARD, J.  355-360
MÉSSELRI, F.H.  307-309
MKHALLIDIS, A.M.  177-181
MKHALLIDIS, D.P.  177-181
MILDEWSKI, P.J.  83-91
MILLEDGE, J.S.  595-604
MILLER, N.E.  397-401
MILLER, P.D.  235-238
MINTY, B.D.  595-604
MOLNAR, J.A.  553-556
MONSON, J.P.  411-420
MOORE, M.R.  183-191
MORDECHOVITZ, D.  431-433
MORGAN, D.B.  77-81, 101-107
MORTON, J.J.  143-149, 373-380
MÜHLBAUER, R.C.  503-508
MÜLLER, V.  193-201
MYANT, N.B.  261-271
NAGATANI, T.  295-297
NARRED, P.B.  367-372
NAVAR, L.G.  573-579
NGUYEN-SIMMONET, H.  403-410
NICHOLLS, M.G.  373-380
NIKOLEN, S.P.  329-336
NOBLE, M.I.M.  311-319
NUTTO, D.  341-342
O’DAY, J.  109-111
OLDER, M.W.J.  595-604
O’RIORDAN, J.L.H.  381-387, 427-429
OZAWA, K.  295-297
PAPPAULOS, S.E.  381-387, 427-429
PARK, P.S.  117
PAYNE, N.N.  595-604
PEIGNOUX, M.  273-277
PERL, M.V.  403-410
PERL, S.I.  561-562
PIAGGI, V.  643-649
PIMPLE, J.  311-319
PISO, E.  683-686
PLOTH, D.W.  573-579
PORTA, M.  239-242
POSTON, L.  563-564
PROVOOST, A.P.  435-437
PUCHELLE, E.  13-16
RAMMER, L.  35-41
RECKLESS, J.P.D.  93-100, 125-129
REES, W.D.W.  343-348
RÉGIO, F.  581-588
REUBEN, A.  515-519
REVILLARD, J.P.  403-410
RICCIARDIELLI, B.  581-588
RICHENS, J.M.  255-259
RIGGERS, A.J.G.  465-469
ROBERTSON, J.J.S.  373-380
ROSE, G.A.  17-19, 421-425
ROSE, M.  279-283
ROUND, J.M.  227-234
ROWLANDSON, R.  311-319
ROYLE, G.T.  553-556
RUSE, W.  109-111
RUSSELL, G.I.  361-366
SANDLER, L.M.  427-429
SARTA, T.  565-566
SCOTT, D.L.  71-76
SCHENK, R.  389-396
SCHERER, B.  611-615
SCHNEIDER, E.G.  471-477
SCHRIER, R.W.  235-238
SHENINK, A.  21-26
SHI, E.C.P.  279-283
SHUTTLEWOOD, R.J.  113-115
SKAGEN, K.  243-245, 605-609
SMITH, J.A.  411-420
SMITH, U.  131-136
SMITH, J.F.M.  589-594
SOLTYS, J.  169-176
SONNENBERG, H.  457-464
STAHL, E.  35-41
STERCHI, E.E.  557-560
STOCKS, J.  93-100, 125-129
STRUUKER-BOUDIER, H.A.J.  589-594
SÚAREZ, D.H.  307-309
SUGGETT, A.J.  93-100
SULAIMAN, S.  17-19, 421-425
SULE, U.  397-401
SUMI, J.  321-328
SUMMERFIELD, G.P.  479-488
SWALES, J.D.  361-366
SWAMINATHAN, R.  77-81, 489-494
SZATALOWICZ, V.L.  235-238
TAKAGI, K.  157-162
TAKASUGI, S.  321-328
TAKESHITA, K.  627-642
TAKITA, M.  627-642
TANAKA, K.  627-642
TAYLOR, E.  617-626
TAYLOR, K.W.  449-455
Author Index

THALASSINOS, N.C. 221–226
THOM, A. 27–33
THOMPSON, G.G. 183–191
THOMPSON, R.P.H. 109–111
THRELFALL, C.J. 83–91
THURSTON, H. 361–366
TOBE, T. 295–297
TOKI, N. 321–328
TOMLINSON, S. 381–387
TRECHSEL, U. 389–396
TREE, M. 373–380
TRIMARCO, B. 581–588
TURNBERG, L.A. 343–348
UNGAR, A. 27–33
VAN ESSEN, H. 589–594
VAN STEENBERGEN, W. 521–528
VANTOL, R. 279–283

VENTURA, E. 643–649
VENTURA, H.O. 307–309
VERESS, A.T. 457–464
VIGORITO, C. 581–588
VINCENT, C. 403–410
VOLPE, M. 581–588
WAGSTAFF, M. 529–540
WAHREN, J. 285–293
WAKELING, A. 677–682
WALES, J.K. 77–81
WALLACE, A.M. 183–191
WALTON, K.W. 71–76, 93–100
WAPOIR, R.A. 617–626
WARD, M.P. 595–604
WATSON, M.L. 27–33
WEBER, P.C. 611–615
WEIGHT, M. 397–401
WESTENFELDER, C. 667–676
WHITEHEAD, J.S. 203–207
WIKSTROM, B. 509–514
WILFORD, K. 83–91
WINER, J. 427–429
WITHEY, W.R. 595–604
WITZGALL, H. 611–615
WOLFE, M.H. 553–556
WOLFE, R.R. 553–556
WOOLLARD, M.L. 177–181
WORWOOD, M. 529–540
YAMAMOTO, K. 157–162
YASUDA, K. 295–297
YOUNG, A. 227–234
ZAHM, J.M. 13–16
ZAREIAN, Z. 489–494
ZENEROLI, M.L. 643–649
ZOLI, M. 683–686
ZUCKER, A. 471–477
1. POLICY OF THE JOURNAL

1.1. Scope

Clinical Science publishes papers in the field of clinical investigation, provided they are of a suit-
able standard and contribute to the advancement of knowledge in this field. The term ‘clinical in-
vestigation’ is used in its broad sense to include studies in animals and the whole range of bio-
chemical, physiological, immunological and other approaches that may have relevance to disease in
man. Studies which are confined to normal sub-
jects, or animals, or are purely methodological in
nature may be acceptable. The material presented
should permit conclusions to be drawn and should
not be only of a preliminary nature. The journal
publishes four types of manuscript, namely invited
Editorial Reviews, Full Papers, Short Communi-
cations and Correspondence. In addition, Clinical
Science publishes abstracts of the proceedings of
the Medical Research Society and also that
Society's Annual Guest Lecture.

1.2. The Editorial Board

The Board comprises Editors for the Medical
Research Society and the Biochemical Society and
a Chairman and Deputy Chairman who are drawn
alternately from the two Societies. Members of the
Board retire after a maximum of 5 years; the
Chairman serves in his capacity for 2 years. The
membership of the Board is designed to cover as
wide a range of interests as possible.

The main function of the Board is to decide on
the acceptability of submitted papers, but it also
deals with general matters of editorial policy.

Financial policy is dealt with separately by the
Committee of Management.

1.3. The editorial process

A submitted paper is first read by the Chairman
of the Editorial Board who then sends it to an
Editor. The latter considers the paper in detail and
sends it to one or more referees (who remain
anonymous) from outside the membership of the
Board. The Editor returns it with his recommend-
tion to the Chairman who then writes formally to
the authors. The ultimate responsibility of accep-
tance for publication lies with the Chairman. If the
Chairman is for any reason unavailable, the Deputy Chairman assumes this function.

1.4. Ethics of investigations on human subjects

Authors must state in the text of their paper the manner in which they have complied, where necessary, with the recommendations on human investigations published in the Medical Research Council report of 1962/63 (British Medical Journal (1964) ii, 178–180). Consent must be obtained from each patient or subject after full explanation of the purpose, nature and risks of all procedures used and the fact that such consent has been given should be recorded in the paper. Papers should also state that the Ethical Committee of the Institution in which the work was performed has given approval to the protocol. The Editorial Board will not accept papers the ethical aspects of which are, in the Board's opinion, open to doubt.

1.5. Originality of papers

Submission of a paper to the Editorial Board is taken to imply that it reports work that has not been published in either the same or a substantially similar form, that it is not under consideration for publication elsewhere in the same form, either in English or in any other language, without the consent of the Editorial Board. This does not usually apply to previous publication of oral communications in brief abstract form. In such cases authors should enclose copies of the abstracts. The author, or in the case of multiple authorship the authors, will be asked to sign a statement vesting the copyright in the publishers. Requests for consent for reproduction of material published in Clinical Science should be addressed to the Editorial Manager.

2. SUBMISSION OF MANUSCRIPTS: GENERAL INFORMATION AND FORMAT

2.1. General

Papers submitted for publication should be sent to the Editorial Manager, Clinical Science, 7 Warwick Court, London WC1R 5DP.

The submission should contain four copies (of which three may be photocopies) of the typescript, Tables, Figures etc. The authors should retain one copy of the paper. The Editorial Board does not accept responsibility for damage or loss of papers submitted, although great care is taken to ensure safety and confidentiality of the typescript during the editorial process. In the case of multiple authorship, the covering letter should indicate that the approval of all co-authors has been obtained.

Papers should be presented so that they are intelligible to the non-specialist reader of the journal. This is particularly important in highly specialized fields and a very brief résumé of the current state of knowledge is usually helpful. Certain types of material, e.g. mathematical formulations requiring more than trivial derivations, should be given in a separate Appendix.

Where the reader is referred to previous works by the same author(s) for important details relevant to the present work, copies or reprints of the publication should be sent with the typescript. This is of particular importance in relation to methodology.

The dates of receipt and acceptance of the paper will be published. If the paper has to be returned to the authors for revision and is not resubmitted within 1 month, the date of receipt will be revised accordingly. Papers returned by authors later than 12 months after the original submission date will be treated as new papers. For Short Communications the published date will always be that of receipt of the final version. It is emphasized that badly presented or unduly long papers will be returned for revision and delays in publication will be inevitable. Similar delays will be incurred if the typescript is not prepared strictly in accordance with the instructions detailed below.

2.2. Full papers

The authors should refer to a current issue of Clinical Science to make themselves familiar with the general layout. Concise presentation is very important for rising costs are a severe constraint on space. The length of manuscript and the number of Figures and Tables must be kept to a minimum. Extensive Tables of data can be deposited with the Royal Society of Medicine (see 2.5). Guidance for Authors is usually published in the January issue of the journal, and revised periodically.

Typescripts should be, in general, arranged as follows:

(a) Title page. Title: this should be as informative as possible, since titles of papers are being increasingly used in indexing and coding for information storage and retrieval. The title should indicate the species in which the observations reported have been made. The numbering of parts in a series of papers is not permitted.

List of authors’ names (degrees and appointments are not required).
Laboratory or Institute of origin.

Key words: for indexing the subject of the paper; they should, if possible, be selected from the current issues of 'Medical Subject Headings' (MeSH), produced by the Index Medicus.

Short title: for use as a running heading in the printed text; it should not exceed forty-five characters and spaces.

Author for correspondence: the name and address of the author to whom queries and requests for reprints should be sent.

(b) Summary. This should be a brief statement arranged in numbered paragraphs of what was done, what was found and what was concluded and should rarely exceed 250 words. Contributors from non-English speaking countries are invited to include a translation of the summary in their own language. Abbreviations should be avoided as far as possible and must be defined. Statistical and methodological details including exact doses should also be avoided unless they are essential to the understanding of the summary.

(c) Introduction. This should contain a clear statement of the reason for doing the work, but should not include either the findings or the conclusions.

(d) Methods. The aim should be to give sufficient information in the text or by reference to permit the work to be repeated without the need to communicate with the author.

(e) Results. This section should not include material appropriate to the Discussion section.

(f) Discussion. This should not contain results and should be pertinent to the data presented.

(g) Acknowledgments. These should be as brief as possible.

(h) References. See p. v for the correct format.

(i) Figures and Tables. See p. iv.

2.3. Short Communications

The Short Communication should describe completed work, and should not be merely a preliminary communication. The format of Short Communications should be similar to that of Full Papers, but should not exceed 1200 words of text. One Figure or Table is allowed, but if neither is included the text may be expanded to 1400 words. The passage of Short Communications through the editorial process can frequently be expedited and contributors are encouraged to take advantage of these facilities when rapid publication is of importance and the material can be presented concisely.

The paper should appear in print within 3 months of acceptance. When submitting Short Communications, authors should make it quite clear that the work is intended to be treated as a Short Communication.

2.4. Correspondence

Letters containing critical assessments of material published in Clinical Science, including Editorial Reviews, will be considered for the Correspondence section of the journal. Letters should be no longer than 750 words, with one Figure or Table and up to six references, or 1000 words maximum without a Figure or Table. Such letters should be sent to the Editorial Manager, Clinical Science, within 6 months of the appearance of the article concerned. They will be sent to the authors for comment and both the letter and any reply by the author will be published together. Further correspondence arising therefrom will also be considered for publication. Consideration will also be given to publication of letters on ethical matters.

Work submitted as a full paper or Short Communication that is assessed by the Editorial Board as unacceptable in that form might be acceptable for publication as a letter.

2.5. Arrangements for large amounts of information

It is impracticable to publish very large sets of individual values or very large numbers of diagrams, and under these circumstances a summary of the information only should be included in the paper. The information from which the summary was derived should be submitted with the typescript and, if the latter is accepted, the Editors may ask for a copy of the full information and diagrams to be deposited with the Librarian, the Royal Society of Medicine, 1 Wimpole Street, London W1M 8AE, who will issue copies on request. Experience has shown that such requests are frequently received.

2.6. Proof corrections

These are expensive and corrections of other than printers' errors may have to be charged to the author.

2.7. Offprints

Fifty offprints are supplied free and additional copies may be obtained at terms, based upon the cost of production, that will be given with the proofs. All offprints should be ordered when the proofs are returned.

2.8. Availability on MEDLINE

Summaries of papers in Clinical Science are available on-line on teleprinters participating in the
3. MISCELLANEOUS NOTES

3.1. Abbreviations
Abbreviations should be avoided; if used they must be defined at the first mention; new abbreviations should be coined only for unwieldy names which occur frequently. Abbreviations should not appear in the title nor, if possible, in the Summary. A list of accepted abbreviations is on p. vi. Numbers, not initials, should be used for patients and subjects.

3.2. Anatomical nomenclature
This should follow the recommendations of the International Anatomical Nomenclature Committee (1966) Nomina Anatomica, 3rd edn, Excerpta Medica Foundation, Amsterdam.

3.3. Animals, plants and micro-organisms
The full binomial specific names should be given at first mention for all experimental animals other than common laboratory animals. The strain and, if possible, the source of laboratory animals should be stated. Thereafter in the text, single letter abbreviations may be given for the genus; if two genera with the same initial letter are studied, abbreviations such as Staph. and Strep. should be used.

3.4. Buffers and salts
The acidic and basic components should be given, together with the pH. Alternatively, a reference to the composition of the buffer should be given. Further details are provided in the Biochemical Journal (1978) 169, 9.

When describing solutions containing organic anions and their parent acids, the salt designator (e.g. lactate, urate, oxalate) should be used in preference to the name of the acid (lactic, uric, oxalic) unless it is certain that virtually all of the acid is in the undissociated form.

The composition of incubation media should be described, or a reference to the composition should be given.

3.5. Computer modelling
Papers concerned primarily with computer modelling techniques are acceptable provided that use of such techniques leads to a clear choice between two or more alternative hypotheses, or to the formulation of a new hypothesis amenable to experimental challenge or verification, or provides some new insight into the behaviour of a particular physiological system. Extensive technical details of hardware and software should not be given.

3.6. Doses
Doses of drugs should be expressed in mass terms, e.g. milligrams (mg) or grams (g), and also (in parentheses) in molar terms, e.g. mmol, mol, where this appears to be relevant. Molecular weights of many drugs may be found in The Merck Index, 8th edn, Merck and Co. Inc., N.J., U.S.A.

3.7. Enzymes
Nomenclature should follow that given in Enzyme Nomenclature (1978), Academic Press, London and New York, and Enzyme Commission (EC) number should be quoted at the first mention. Where an enzyme has a commonly used informal name, this may be employed after the first formal identification. A unit of enzyme activity should preferably be expressed as that amount of material which will catalyse transformation of 1 μmol of the substrate/min under defined conditions, including temperature and pH. Alternatively, or when the natural substrate has not been fully defined, activity should be expressed in terms of units of activity relative to that of a recognized reference preparation, assayed under identical conditions. Activities of enzymes should normally be expressed as units/ml or units/mg of protein.

3.8. Evaluation of measurement procedures
When a new measuring procedure has been used, or when an established procedure has been applied in a novel fashion, an estimate of the precision of the procedure should be given. This should, as far as possible, indicate what sources of variation have been included in this estimate, e.g. variation of immediate replication, variation within different times of day, or from day to day etc.

If the precision of measurement varies in proportion to the magnitude of the values obtained, it can best be expressed as the coefficient of variation; otherwise it should be expressed by an estimate of the (constant) standard error of a single observation, or by estimates at several points within the range of observed values.

When recovery experiments are described the approximate ratio of the amount added to the amount already present and the stage of the procedure at which the addition was made should be stated.

3.9. Figures and Tables
These are expensive to print and their number should be kept to a minimum. Their appropriate
position in the paper should be indicated in the margin of the text. References to Figures and Tables should be in Arabic numerals, e.g. Fig. 3, and they should be numbered in order of appearance. In general, the same data should not be presented in both a Figure and a Table.

Figures, with captions attached, should be supplied as original drawings or matt photographs together with photocopies. All Figures should have their number and the authors' names written in pencil on the back; the top of the Figure should be indicated with a pencilled arrow. Acceptable symbols for experimental points are ◊, ▲, ■, ○, △, □. The symbols × or + must be avoided. The same symbols must not be used for two curves where the points might be confused. For scatter diagrams, solid symbols are preferred. When a particular variable appears in more than one Figure, the same symbol should be used for it throughout, if possible.

Curves should not be drawn beyond the experimental points, nor should axes extend appreciably beyond the data. Only essential information that cannot readily be included in the legend should be written within the Figure.

Figures for half-tone reproduction should be submitted as glossy prints. They are particularly expensive to print and their use should be avoided as far as possible.

Tables should be typed separately from the text. They should have an underlined title followed by any legend.

Captions for the Figures, and titles and legends for the Tables, should make them readily understandable without reference to the text. Adequate statistical information, including that on regression lines, should be included in Figure captions where appropriate.

3.10. Footnotes
These should be avoided as far as possible but where they are used in Tables they should be identified by the symbols * † ‡ § ‖ ¶, in that order.

3.11. Isotope measurements
The information given should include (a) conditions of radioactivity counting, e.g. infinitely thick, infinitely thin; (b) the nature of the phosphor used in liquid-scintillation counting; (c) details of corrections made to the observed count rate, e.g. for 'quenching' or 'cross-over'; (d) standard deviation of the results or a statement of the minimum total counts above background collected and the background value.

In general the specific radioactivity of the starting materials should be given, preferably in terms of radioactivity per unit weight or, for stable isotopes, as atoms % excess.

Pending the general introduction of SI units radioactivity should continue to be expressed in terms of the becquerel (Bq: disintegrations/s), in parentheses, and suitably rounded.

3.12. Radionuclide applications in man
If new or modified radionuclide applications in man are described, an estimate of the maximal possible radiation dose to the body and critical organs should be given.

For the time being this can continue to be expressed in rems, but with the corresponding figure in sieverts (Sv) given in parentheses after it.

3.13. Methods
In describing certain techniques, namely centrifugation (when the conditions are critical), chromatography and electrophoresis, authors should follow the recommendations published by the Biochemical Society (currently, Biochemical Journal (1981) 193, 1–21).

This should follow the International Classification of Disease (8th revision, World Health Organization, Geneva, 1969) as far as possible.

3.15. Powers in Tables and Figures
Care is needed where powers are used in Table headings and in Figures to avoid numbers with an inconvenient number of digits. For example: (i) an entry '2' under the heading $10^k$ means that the value of $k$ is 0.002; an entry '2' under the heading $10^{-2}$ means that the value of $k$ is 2000. (ii) A concentration 0.00015 mol/l may be expressed as 0.15 under the heading 'concn. (mmol/l)' or as 150 under the heading 'concn. ($\mu$mol/l)' or as 15 under the heading $10^2 \times$ concn. (mol/l), but not as 15 under the heading 'concn. (mol/l) $\times 10^{-2}$'.

3.16. References
The numerical citation system is now used: references in the text are numbered consecutively in the order in which they are first mentioned, the numerals being given in brackets, e.g. [22]. References cited in Figure legends or Tables only should be numbered in a sequence determined by the position of the first mention in the text of the Figure or Table. References should be listed in
numerical order and the names of all authors of a paper should be given, with the full title of the paper and the source details in full including the first and last page numbers, e.g.


When the quotation is from a book, the following format should be used, giving the relevant page or chapter number:


References to 'personal communications' and 'unpublished work' should appear in the text only and not in the list of references. The name and initials of the source of information should be given. When the reference is to material that has been accepted for publication but has not yet been published, this should be indicated in the list of references by 'In press' together with the name of the relevant journal and, if possible, the expected date of publication. If such a citation is of major relevance to the manuscript submitted for publication authors are advised that the editorial process might be expedited by the inclusion of a copy of such work. In the case of quotations from personal communications the authors should state in the covering letter that permission for quotation has been obtained.

3.17. Solutions

Concentration of solutions should be described where possible in molar terms (mol/l and subunits thereof), stating the molecular particle weight if necessary. Values should not be expressed in terms of normality or equivalents. Mass concentration should be expressed as g/l or subunits thereof, for example mg/l or μg/l. For solutions of salts, molar concentration is always preferred to avoid ambiguity as to whether anhydrous or hydrated compounds are used. Concentrations of aqueous solutions should be given as mol/l or mol/kg (g/l or g/kg if not expressed in molar terms) rather than % (w/v) or % (w/w). It should always be made clear whether concentrations of components in a reaction mixture are final concentrations or the concentrations in solutions added.

3.18. Spectrophotometric data

The term 'absorbance' \( \log (I/o/I) \) should be used rather than 'optical density' or 'extinction'. The solvent, if other than water, should be specified. Symbols used are: \( A \), absorbance; \( a \), specific absorption coefficient (litre g\(^{-1}\) cm\(^{-1}\)) (alternatively use \( A_{1\%}^{1\%} \)); \( e \), molar absorption coefficient (the absorbance of a molar solution in a 1 cm light-path) (litre mol\(^{-1}\) cm\(^{-1}\), not cm\(^2\) mol\(^{-1}\)).

3.19. Spelling


3.20. Statistics

Papers are frequently returned for revision (and their publication consequently delayed) because the authors use inappropriate statistical methods. Two common errors are the use of means, standard deviations and standard errors in the description and interpretation of grossly non-normally distributed data and the application of \( t \)-tests for the significance of difference between means in similar circumstances, or when the variances of the two groups are non-homogeneous. In some circumstances it may be more appropriate to provide a 'scattergram' than a statistical summary.

A reference should be given for all methods used to assess the probability of a result being due to chance. The format for expressing mean values and standard deviations or standard errors of the mean is, for example: mean cardiac output 10.4 l/min (SD 1.2; \( n = 11 \)). Degrees of freedom should be indicated where appropriate. Levels of significance are expressed in the form \( P < 0.01 \).

3.21. Trade names

The name and address of the supplier of special apparatus and of biochemicals should be given. In the case of drugs, approved names should always be given with trade names and manufacturers in parentheses.

4. UNITS: THE SI SYSTEM

The recommended Système International (SI) units [see Quantities, Units and Symbols, 2nd edn (1975) The Royal Society, London] are used by Clinical Science. All papers submitted should use these units except for blood pressure values, which should be expressed in mmHg, or gas tensions, where values at the author's discretion may be given as mmHg (with kPa in parentheses) or as kPa (with mmHg in parentheses) in the text and either as mmHg or as kPa in Figures, which (if practicable) should have scales in both units. Airways pressure should be expressed in kPa. Where molecular weight is known, the amount of a chemical or drug should be expressed in mol or in
an appropriate subunit, e.g. mmol. Energy should be expressed in joules (J).

The basic SI units and their symbols are as follows:

<table>
<thead>
<tr>
<th>Physical quantity</th>
<th>Name</th>
<th>Symbol</th>
</tr>
</thead>
<tbody>
<tr>
<td>length</td>
<td>metre</td>
<td>m</td>
</tr>
<tr>
<td>mass</td>
<td>kilogram</td>
<td>kg</td>
</tr>
<tr>
<td>time</td>
<td>second</td>
<td>s</td>
</tr>
<tr>
<td>electric current</td>
<td>ampere</td>
<td>A</td>
</tr>
<tr>
<td>thermodynamic</td>
<td>kelvin</td>
<td>K</td>
</tr>
<tr>
<td>temperature</td>
<td>candelal</td>
<td>cd</td>
</tr>
<tr>
<td>luminous intensity</td>
<td>mole</td>
<td>mol</td>
</tr>
</tbody>
</table>

The following are examples of derived SI units:

<table>
<thead>
<tr>
<th>Physical quantity</th>
<th>Name</th>
<th>Symbol</th>
</tr>
</thead>
<tbody>
<tr>
<td>energy</td>
<td>joule</td>
<td>J</td>
</tr>
<tr>
<td>force</td>
<td>newton</td>
<td>N</td>
</tr>
<tr>
<td>power</td>
<td>watt</td>
<td>W</td>
</tr>
<tr>
<td>pressure</td>
<td>pascal</td>
<td>Pa</td>
</tr>
<tr>
<td>electric charge</td>
<td>coulomb</td>
<td>C</td>
</tr>
<tr>
<td>electric potential</td>
<td>volt</td>
<td>V</td>
</tr>
<tr>
<td>electric resistance</td>
<td>ohm</td>
<td>Ω</td>
</tr>
<tr>
<td>electric conductance</td>
<td>siemens</td>
<td>S</td>
</tr>
<tr>
<td>electric capacitance</td>
<td>farad</td>
<td>F</td>
</tr>
<tr>
<td>frequency</td>
<td>hertz</td>
<td>Hz</td>
</tr>
<tr>
<td>volume</td>
<td>litre</td>
<td>l</td>
</tr>
</tbody>
</table>

The word ‘litre’ has been accepted as a special name for cubic decimetre (1 litre = 1 dm³).

Both the basic and derived SI units, including the symbols of derived units that have special names, may be preceded by prefixes to indicate multiples and submultiples. The prefixes should be as follows:

<table>
<thead>
<tr>
<th>Prefix</th>
<th>Symbol</th>
<th>Multiple</th>
<th>Prefix</th>
<th>Symbol</th>
</tr>
</thead>
<tbody>
<tr>
<td>10⁶</td>
<td>mega</td>
<td>10⁻³</td>
<td>milli</td>
<td>m</td>
</tr>
<tr>
<td>10³</td>
<td>kilo</td>
<td>10⁻⁶</td>
<td>micro</td>
<td>μ</td>
</tr>
<tr>
<td>10²</td>
<td>hecto</td>
<td>10⁻⁹</td>
<td>nano</td>
<td>n</td>
</tr>
<tr>
<td>10⁻¹</td>
<td>deka</td>
<td>10⁻¹²</td>
<td>pico</td>
<td>p</td>
</tr>
<tr>
<td>10⁻²</td>
<td>deci</td>
<td>10⁻¹⁵</td>
<td>femto</td>
<td>f</td>
</tr>
</tbody>
</table>

* To be avoided where possible (except for cm).

Compound prefixes should not be used, e.g. 10⁻⁹ m should be represented by 1 nm, not 1 μm.

Notes:

(i) Full stops are not used after symbols.
(ii) Minutes (min), hours (h), days and years will continue to be used in addition to the SI unit of time (the second (s)).
(iii) The solidus may be used in a unit as long as it does not have to be employed more than once,

<table>
<thead>
<tr>
<th>Physical quantity</th>
<th>Name</th>
<th>Symbol</th>
</tr>
</thead>
<tbody>
<tr>
<td>absorbance</td>
<td>A</td>
<td></td>
</tr>
<tr>
<td>acceleration due</td>
<td>g</td>
<td></td>
</tr>
<tr>
<td>to gravity</td>
<td>cyclic AMP</td>
<td></td>
</tr>
<tr>
<td>adenosine 3’:5’-cyclic monophosphate</td>
<td>AMP</td>
<td></td>
</tr>
<tr>
<td>adenosine 5’-phosphate</td>
<td>ADP</td>
<td></td>
</tr>
<tr>
<td>adenosine 5’-triphosphate</td>
<td>ATP</td>
<td></td>
</tr>
<tr>
<td>adenosine triphosphatase</td>
<td>ATPase</td>
<td></td>
</tr>
<tr>
<td>adrenocorticotropic hormone</td>
<td>ACTH</td>
<td></td>
</tr>
<tr>
<td>adrenoceptor</td>
<td>Ala</td>
<td></td>
</tr>
<tr>
<td>alternating current</td>
<td>a.c.</td>
<td></td>
</tr>
<tr>
<td>alveolar minute ventilation</td>
<td>V A</td>
<td></td>
</tr>
<tr>
<td>alveolar to arterial oxygen tension difference</td>
<td>(Pao₂ - PaO₂)</td>
<td></td>
</tr>
<tr>
<td>ampere</td>
<td>A</td>
<td></td>
</tr>
<tr>
<td>aminolaevulinic acid</td>
<td>ALA</td>
<td></td>
</tr>
<tr>
<td>angiotensin</td>
<td>Ang</td>
<td></td>
</tr>
<tr>
<td>Angstrom (Å)</td>
<td>not used</td>
<td></td>
</tr>
<tr>
<td>antidiuretic hormone</td>
<td>ADH (when referring to the physiological secretion)</td>
<td></td>
</tr>
<tr>
<td>arginine</td>
<td>Arg</td>
<td></td>
</tr>
<tr>
<td>arteriovenous</td>
<td>a-v: permitted in Figures and Tables</td>
<td></td>
</tr>
<tr>
<td>asparagine</td>
<td>Asn</td>
<td></td>
</tr>
<tr>
<td>aspartic acid</td>
<td>Asp</td>
<td></td>
</tr>
<tr>
<td>atmosphere (unit of pressure)</td>
<td>not used; express in kPa (1 atmosphere = 101.325 kPa)</td>
<td></td>
</tr>
<tr>
<td>atomic weight</td>
<td>at. wt.</td>
<td></td>
</tr>
<tr>
<td>becquerel</td>
<td>Bq</td>
<td></td>
</tr>
<tr>
<td>blocking agents</td>
<td>e.g. β-adrenoceptor antagonists preferred</td>
<td></td>
</tr>
<tr>
<td>blood pressure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>blood urea nitrogen</td>
<td>not used; recalculate as urea, express in mmol/l</td>
<td></td>
</tr>
<tr>
<td>blood volume</td>
<td>BV</td>
<td></td>
</tr>
<tr>
<td>body temperature</td>
<td>BTPS</td>
<td></td>
</tr>
</tbody>
</table>

As well as standard symbols and abbreviations that have been accepted by international bodies, and which can be used without definition, this list shows selected abbreviations in the form of groups of capital letters (e.g. ALA, ECF, MCHC) which when used must be defined in the text as indicated on p. iv. The standard abbreviations for amino acids are only for use in Figures and Tables or for peptide sequences.
British Pharmacopoeia

calculated

‘Calorie’ (= 1000 cal)
calc. (in Tables only)

not used; recalculate as kilojoules (1 ‘Calorie’ = 4.184 kJ)

\[
V_{CO_2} \text{ express in ml STP/min}
\]
f ; in beats/min

express in l/min cm

\[
C_t
\]
\[
\text{CoA and acyl-CoA}
\]
cf.

C1–C9

C; express in 1 kPa–1

conc.

conc.; may be denoted \[1\] e.g. plasma [HCO_3^-]

\[
G; \text{ express in } 1 \text{s}^{-1} \text{kPa}^{-1}
\]

\[
r; \text{ may be used without definition}
\]
c.p.m., c.p.s.

use ml Ci (1 Ci = \[3.7 \times 10^{10}\] d.p.s.)

Hz

Cys

e.g. 11 August 1970

\[
V_D\]

\[
\text{DOCA}
\]

DNA
diffuse preferred; ‘dialysate’ should be clearly defined

DEAE-cellulose

\[x (= dx/dr)\]

1.25-(OH)_2D_3

dil.

2.3-DPG
d.e.

d.p.m.

d.p.s.

\[
K_a
\]

\[
K_b
\]

\[
e.g. K'_a
\]

pK

avoid Latin designations such as b.d. and t.i.d.
dyn; used for vascular resistance

\[E; \text{ express in Pa m}^{-3}\]

ECG

EEG

electromotive force

electron spin resonance
electronvolt

equation
equivalents (amount of a chemical)

erthrocyte count

erthrocyte sedimentation rate

ethanol, ethanolic

ethylendiaminnetetra-acetate exchangeable

Experiment (with reference numeral)

expired minute ventilation

extinction

extracellular fluid

extracellular fluid volume

extraction ratio of x (renal)

Figure (with reference numeral)

filtered load of x (renal)

follicle-stimulating hormone

forced expiratory volume in 1-0 s

fractional concentration in dry gas

fractional disappearance rate

frequency of respiration

functional residual capacity

gas–liquid chromatography

gas transfer factor

glomerular filtration rate

glutamic acid

glutathione

glycine

gram(me)

gravitational field, unit of \([9.81 \text{ m s}^{-2}]\)

growth hormone

guery

haemoglobin

half-life

histidine

hour

human chorionic gonadotropin

human placental lactogen

hydrocortisone

hydrogen ion activity

minus log of

25-hydroxycholecalciferol

hydroxyproline

immunoglobulins

e.m.f.
e.s.r.
eV (for radiation energies)
eqn.

not used; recalculate in molar terms

express as \(10^{12}\) cells/l

ESR

not ethyl alcohol or alcoholic

EDTA

Na_+, K_+ etc., for total exchangeable sodium, potassium etc.

Expt.; plural, Expts.

\[
V_{E}\]

use absorbance

ECF

ECFV

\[E_r\]

Fig.; plural, Figs.

\[F_r\]

FSH

FEV_{1-0}

\[F\]

k (as in \[A = Ae^{-kt}\])

\[
V_{F_E}\]

in breaths/min

FRC

g.l.c.

\[T; \text{ in mmol min}^{-1} \text{kPa}^{-1}\]

GFR

Glu

Gln

GSH (reduced); GSSG (oxidized)

Gty

\[g\]

G

GH; if human, HGH

Gy (100 rads)

not allowed; use packed cell volume (PCV)

Hb; express in g/dl

\[l_i\]

Hz

His

H

HCG

HPL

use cortisol

\[aH; \text{ express in nmmol/l}\]

pH

25-(OH)_2D_3

Hyp

IgA, IgD, IgE, IgG, IgM

Guidance for Authors

write in full and give edition

not used; recalculate as kilojoules (1 ‘Calorie’ = 4.184 kJ)

calculate

calc. (in Tables only)

not used; recalculate as kilojoules (1 ‘Calorie’ = 4.184 kJ)
injection routes:
- intra-arterial (i.a.)
- intramuscular (i.m.)
- intraperitoneal (i.p.)
- intravenous (i.v.)
- subcutaneous (s.c.)

International Unit

Intracellular fluid

Intracellular fluid volume

Ionic strength

Isoleucine

Isotonic

Isotopically labelled compounds

Joule

Kilogram (kg)

Kilopond

Lactate dehydrogenase

Leucine

Leucocyte count

Lipoproteins (serum)

High density

Low density

Very low density

Litre

Logarithm (base 10)

Logarithm (base e)

Luteinizing hormone

Lysine

Maximum

Mean corpuscular haemoglobin

Mean corpuscular haemoglobin concentration

Mean corpuscular haemoglobin volume

Median lethal dose

Methanol

Methanolic

Methionine

Metre

Michaelis constant

Micromole

Micron (10^-6 m)

Milliequivalent

Millilitre

Guidance for Authors

Millimetre of mercury

Millimolar (concentration)

Millimol

Minimum

Minute (60 s)

Molal

Molar (concentration)

Molar absorption coefficient

Mole

Molecular weight

Nicotinamide-adenine dinucleotide

Nicotinamide-adenine dinucleotide phosphate

Normal

Normal temperature and pressure

Nuclear magnetic resonance

Number (in enumerations)

Observed

Ohm

Ornithine

Ortho-

Orthophosphate (inorganic)

Osmolarity

Oxygen uptake per minute

Pack cell volume

Page, pages

Para-

Para-aminohippurate

Partial pressure

E.g. alveolar, of O₂

Arterial, of O₂

Capillary, of O₂

Mixed venous, of O₂

Pascal

Per

Percent

Petroleum ether

Phenylalanine

Plasma renin activity

Plasma volume

Poise

Poise

Pascal

Per cent

Petroleum and give boiling range

Phe

Express as pmol of angiotensin I h⁻¹ ml⁻¹

PV

1 poise = 10⁻¹ N s m⁻²
Guidance for Authors

potential difference
power output
precipitate
pressure
probability of an event being due to chance alone
proline
protein-bound iodine (plasma)
pulmonary capillary blood flow
pyrophosphate (inorganic)
radiation dose
red blood cell
red cell mass
relative band speed (partition chromatography)
renin
residual volume
resistance (rheological)
respiratory exchange ratio (pulmonary)
respiratory quotient (metabolic)
revolutions
ribonucleic acid
röntgen
saline
saturation
second (time)
serine
sievert
solvent systems
species
specific activity

$p.d.$
$W$ (1 W = 0.1635 kpm/min)
$ppt.$
$P_r$ (except for blood pressures and gas tensions: see p. 6);
$1$ kPa = 7.5 mm Hg
$P$
$Pro$
$PBI$
$Q_c$
$PPi$
$P_{Pro}$
$P_{BI}$
$Q_c$
$RCM$
$R_F$
$100$ ergs/g $\times$ quality factor
$RNA$
$R$
$S$, e.g. $S_aO_2$, for arterial oxygen saturation
$s$
$Ser$
$Sv$ (1 J/kg $\times$ quality factor)
e.g. butanol/acetetic acid/water (4:1:1, by vol.), butanol/acetetic acid (4:1, v/v)
sp., plural spp.
sp. act. Confusion must be avoided between e.g. specific radioactivity and the specific activity of an enzyme

specific conductance of airways
standard deviation
standard error of the mean
standard temperature and pressure
steroid nomenclature
sulphhydryl
sum
Svedberg unit
temperature (absolute)
(temperature, thermodynamic)
thin-layer chromatography
threonine
thyrotrophic hormone
thyrotrophin-releasing hormone
tidal volume
time (symbol)
time of day
torr
total lung capacity
tryptophan
tubular maximal reabsorptive capacity for x
tyrosine
ultraviolet
urinary concentration of x
valence
variance ratio
vascular resistance

$\Sigma$
$S$
$T$
$t$
$^\circ K$
not abbreviated
$100$ rads = 1 Gy
$10^3$ cells/l
$V_r$
torrs
$1$ kPa
$1$ Gy
$V_r$
torrs
$10^3$ cells/l
$\nu$
$U_s$
e.g. $Fe^{++}$, not $Fe^{++}$
$Val$
$F$

express in $s^{-1}$ kPa$^{-1}$
may be used without definition
see Biochemical Journal
(1969) 113, 5-28;
(1972) 127, 613-617
use thiol or SH
$T_{m,x}$
$\nu$
$U_s$
e.g. $Fe^{++}$, not $Fe^{++}$
$Val$
$F$

express in $s^{-1}$ kPa$^{-1}$
may be used without definition
see Biochemical Journal
(1969) 113, 5-28;
(1972) 127, 613-617
use thiol or SH
$T_{m,x}$
$\nu$
$U_s$
e.g. $Fe^{++}$, not $Fe^{++}$
$Val$
$F$

express in $s^{-1}$ kPa$^{-1}$
may be used without definition
see Biochemical Journal
(1969) 113, 5-28;
(1972) 127, 613-617
use thiol or SH
$T_{m,x}$
$\nu$
$U_s$
e.g. $Fe^{++}$, not $Fe^{++}$
$Val$
$F$

express in $s^{-1}$ kPa$^{-1}$
may be used without definition
see Biochemical Journal
(1969) 113, 5-28;
(1972) 127, 613-617
use thiol or SH
$T_{m,x}$
$\nu$
$U_s$
e.g. $Fe^{++}$, not $Fe^{++}$
$Val$
$F$

express in $s^{-1}$ kPa$^{-1}$
may be used without definition
see Biochemical Journal
(1969) 113, 5-28;
(1972) 127, 613-617
use thiol or SH
$T_{m,x}$
$\nu$
$U_s$
e.g. $Fe^{++}$, not $Fe^{++}$
$Val$
$F$

express in $s^{-1}$ kPa$^{-1}$
may be used without definition
see Biochemical Journal
(1969) 113, 5-28;
(1972) 127, 613-617
use thiol or SH
$T_{m,x}$
$\nu$
$U_s$
e.g. $Fe^{++}$, not $Fe^{++}$
$Val$
$F$

express in $s^{-1}$ kPa$^{-1}$
may be used without definition
see Biochemical Journal
(1969) 113, 5-28;
(1972) 127, 613-617
use thiol or SH
$T_{m,x}$
$\nu$
$U_s$
e.g. $Fe^{++}$, not $Fe^{++}$
$Val$
$F$

express in $s^{-1}$ kPa$^{-1}$
may be used without definition
see Biochemical Journal
(1969) 113, 5-28;
(1972) 127, 613-617
use thiol or SH
$T_{m,x}$
$\nu$
$U_s$
e.g. $Fe^{++}$, not $Fe^{++}$
$Val$
$F$

express in $s^{-1}$ kPa$^{-1}$
may be used without definition
see Biochemical Journal
(1969) 113, 5-28;
(1972) 127, 613-617
use thiol or SH
$T_{m,x}$
$\nu$
$U_s$
e.g. $Fe^{++}$, not $Fe^{++}$
$Val$
$F$

express in $s^{-1}$ kPa$^{-1}$
may be used without definition
see Biochemical Journal
(1969) 113, 5-28;
(1972) 127, 613-617
use thiol or SH
$T_{m,x}$
$\nu$
$U_s$
e.g. $Fe^{++}$, not $Fe^{++}$
$Val$
$F$

express in $s^{-1}$ kPa$^{-1}$
may be used without definition
see Biochemical Journal
(1969) 113, 5-28;
(1972) 127, 613-617
use thiol or SH
$T_{m,x}$
$\nu$
$U_s$
e.g. $Fe^{++}$, not $Fe^{++}$
$Val$
$F$

express in $s^{-1}$ kPa$^{-1}$
may be used without definition
see Biochemical Journal
(1969) 113, 5-28;
(1972) 127, 613-617
use thiol or SH
$T_{m,x}$
$\nu$
$U_s$
e.g. $Fe^{++}$, not $Fe^{++}$
$Val$
$F$

express in $s^{-1}$ kPa$^{-1}$
may be used without definition
see Biochemical Journal
(1969) 113, 5-28;
(1972) 127, 613-617
use thiol or SH
$T_{m,x}$
$\nu$
$U_s$
e.g. $Fe^{++}$, not $Fe^{++}$
$Val$
$F$
<table>
<thead>
<tr>
<th>Subject</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absorption kinetics</td>
<td>617–626</td>
</tr>
<tr>
<td>Adenine nucleotides, dystrophic muscle</td>
<td>113–115</td>
</tr>
<tr>
<td>Adenosine 3':5'-cyclic monophosphate, vitamin D deficiency</td>
<td>381–387</td>
</tr>
<tr>
<td>Adenosine triphosphatase, Na+,K+-activated, erythrocyte sodium transport</td>
<td>489–494</td>
</tr>
<tr>
<td>Adrenectomy, angiotensinogen</td>
<td>355–360</td>
</tr>
<tr>
<td>Adrenaline</td>
<td></td>
</tr>
<tr>
<td>airway responses</td>
<td>349–354</td>
</tr>
<tr>
<td>congestive heart failure</td>
<td>465–469</td>
</tr>
<tr>
<td>noise stimulation</td>
<td>137–141</td>
</tr>
<tr>
<td>β-Adrenoceptor blockade, diabetic subjects</td>
<td>131–136</td>
</tr>
<tr>
<td>β-Adrenoceptors, asthma</td>
<td>349–354</td>
</tr>
<tr>
<td>Aerosol deposition, bronchial</td>
<td>13–16</td>
</tr>
<tr>
<td>Alanine</td>
<td></td>
</tr>
<tr>
<td>kinetics and glucose</td>
<td>553–556</td>
</tr>
<tr>
<td>obesity</td>
<td>77–81</td>
</tr>
<tr>
<td>Albuminuria, experimental</td>
<td>495–502</td>
</tr>
<tr>
<td>Alcohol, hypertension</td>
<td>1–6*</td>
</tr>
<tr>
<td>Aldosterone</td>
<td></td>
</tr>
<tr>
<td>captopril</td>
<td>611–615</td>
</tr>
<tr>
<td>congestive heart failure</td>
<td>465–469</td>
</tr>
<tr>
<td>exercise</td>
<td>595–604</td>
</tr>
<tr>
<td>potassium</td>
<td>373–380</td>
</tr>
<tr>
<td>salt retention in bile-duct ligation</td>
<td>65–70</td>
</tr>
<tr>
<td>sodium balance</td>
<td>373–380</td>
</tr>
<tr>
<td>Alkali secretion, gastric mucosa</td>
<td>343–348*</td>
</tr>
<tr>
<td>Alveolar gas, mixing efficiency</td>
<td>541–547, 549–551</td>
</tr>
<tr>
<td>Amino acids</td>
<td></td>
</tr>
<tr>
<td>metabolism and α-oxoisocaproate</td>
<td>285–293</td>
</tr>
<tr>
<td>undernutrition and sepsis</td>
<td>83–91</td>
</tr>
<tr>
<td>δ-[3,5-3H]Aminolaevulinic acid, bile pigment production</td>
<td>643–649</td>
</tr>
<tr>
<td>δ-Aminolaevulinic acid synthase, leucocyte</td>
<td>183–191</td>
</tr>
<tr>
<td>Ammonia</td>
<td></td>
</tr>
<tr>
<td>glutamine</td>
<td>299–305</td>
</tr>
<tr>
<td>hepatectomy</td>
<td>273–277</td>
</tr>
<tr>
<td>α-oxoisocaproate</td>
<td>285–293</td>
</tr>
<tr>
<td>urinary excretion</td>
<td>299–305</td>
</tr>
<tr>
<td>Ammoniagenesis, glutamine metabolism</td>
<td>299–305</td>
</tr>
<tr>
<td>Angina pectoris</td>
<td>119–123*</td>
</tr>
<tr>
<td>Angiotensin I</td>
<td></td>
</tr>
<tr>
<td>angiotensinogen</td>
<td>355–360</td>
</tr>
<tr>
<td>captopril and vasopressin release</td>
<td>341–342</td>
</tr>
<tr>
<td>Angiotensin II</td>
<td></td>
</tr>
<tr>
<td>aldosterone</td>
<td>373–380</td>
</tr>
<tr>
<td>blood flow regulation</td>
<td>169–176</td>
</tr>
<tr>
<td>captopril</td>
<td>341–342</td>
</tr>
<tr>
<td>congestive heart failure</td>
<td>465–469</td>
</tr>
<tr>
<td>intravascular coagulation</td>
<td>35–41</td>
</tr>
<tr>
<td>kidney</td>
<td>35–41</td>
</tr>
<tr>
<td>sympathetic reflexes</td>
<td>51–56</td>
</tr>
<tr>
<td>vasopressin</td>
<td>143–149, 341–342</td>
</tr>
<tr>
<td>Angiotensin antagonist ([Sar¹,Ala²]angiotensin II)</td>
<td>51–56</td>
</tr>
<tr>
<td>Angiotensinogen, direct radioimmunoassay</td>
<td>355–360</td>
</tr>
<tr>
<td>Anorexia nervosa, behavioural thermoregulation</td>
<td>677–682</td>
</tr>
<tr>
<td>Antidiuretic hormone, experimental congestive heart failure</td>
<td>465–469</td>
</tr>
<tr>
<td>Apnoea, sleep and heart rate</td>
<td>163–167</td>
</tr>
<tr>
<td>Apolipoprotein C-III, acquired deficiency</td>
<td>93–100</td>
</tr>
<tr>
<td>Apolipoproteins</td>
<td>125–129*</td>
</tr>
<tr>
<td>Aprotinin, Goldblatt hypertension</td>
<td>361–366</td>
</tr>
<tr>
<td>Aspartate aminotransferase, heart isoenzymes</td>
<td>337–339</td>
</tr>
<tr>
<td>Asphyxia, apnoeic, heart rate</td>
<td>163–167</td>
</tr>
<tr>
<td>Asthma</td>
<td></td>
</tr>
<tr>
<td>nocturnal</td>
<td>349–354</td>
</tr>
<tr>
<td>plasma histamine and catecholamines</td>
<td>661–665</td>
</tr>
<tr>
<td>Atherosclerosis, coronary</td>
<td>119–123*</td>
</tr>
<tr>
<td>Atrophy, number of muscle fibres</td>
<td>227–234</td>
</tr>
<tr>
<td>Atropine, alveolar gas mixing</td>
<td>549–551</td>
</tr>
<tr>
<td>Autonomic nervous system</td>
<td></td>
</tr>
<tr>
<td>blockade</td>
<td>57–64</td>
</tr>
<tr>
<td>hypertension</td>
<td>581–588</td>
</tr>
<tr>
<td>Autonomic neuropathy</td>
<td>561–562</td>
</tr>
<tr>
<td>Baroreceptors</td>
<td></td>
</tr>
<tr>
<td>borderline hypertension</td>
<td>307–309</td>
</tr>
<tr>
<td>sensitivity</td>
<td>581–588</td>
</tr>
<tr>
<td>Baroreflex sensitivity</td>
<td>581–588, 589–594</td>
</tr>
<tr>
<td>Behaviour, thermoregulation</td>
<td>677–682</td>
</tr>
<tr>
<td>N-Benzoyl-L-tyrosyl-L-aminobenzoic acid, intestinal non-pancreatic hydrolysis</td>
<td>557–560</td>
</tr>
<tr>
<td>Bicarbonate secretion, duodenal taurocholate</td>
<td>651–659</td>
</tr>
<tr>
<td>Bicarbonate, tubular absorption</td>
<td>667–676</td>
</tr>
</tbody>
</table>
Subject Index

Bile acids
  duodenal perfusion 651–659
  3β-hydroxylated 627–642
  kidney function 431–433
  muscular dystrophy 627–642
  secretion 515–519
Bile-duct ligation, salt retention 65–70
Bile, intrarenal infusion 431–433
Bile salts, secretion 515–519
Bilirubin
  conjugation and secretion 521–528
  Gilbert’s syndrome 643–649
  duodenal taurocholate 651–659
Blood coagulation factors 239–242
Blood flow
  captopril 169–176
  cerebral 567–572*
  haemorrhage 169–176
  hypertension 457–464
  meclofenamate 169–176
  prostaglandins 169–176
  spleen 169–176
  subcutaneous 605–609
Blood pressure
  captopril 611–615
  indomethacin 611–615
  noise stimulation 137–141
  sympathetic reflexes 51–56
  vasopressin 143–149
Blood vessels
  intravascular coagulation 35–41
  renal vascular resistance 573–579
  veno-arteriolar reflex 605–609
Blood volume
  central 51–56
  expansion 457–464
Body fluid
  composition in hypertension 43–49
  homeostasis in exercise 595–604
Body temperature
  anorexia nervosa 677–682
  hepatectomy 273–277
Bone
  mass, parathyroid hormone 389–396
  mineral content 329–336
Brain
  blood flow and metabolism 567–572*
  branched-chain amino acids, metabolism and
    α-oxoisocaproate 285–293
Breathing
  pulmonary inflation reflex 163–167
  resistive load detection 367–372
  thoracoabdominal movements 7–11*
Bronchi, mucociliary clearance 13–16
Bronchodilatation, nocturnal asthma 349–354
Bronchomotor tone, atropine 549–551
Caerulin, bilirubin secretion 651–659
Calcium
  renal tubular absorption 503–508
  neutron activation analysis 389–396
  tubular absorption 503–508
Calcium balance, osteoporosis and sex hormones 221–226
Calcium oxalate, urinary, 17–19, 421–425, 509–514
C-α-proteins 125–129*
Captopril
  adrenergic vasoconstriction 565–566
  blood flow regulation 169–176
  vasopressin release 341–342
Carbohydrate, insulin biosynthesis 449–455*
Catecholamines, asthma 661–665
Cell membrane permeability 101–107
Cerebral blood flow 567–572*
Chemoreceptors, sleep apnoea and heart rate 163–167
Chloretazine, urine osmolality in oedema 235–238
Cholelithiasis 515–519
Cholestasis, erythrocyte membrane permeability 101–107
Cholesterol
  biliary secretion 515–519
  liver 515–519
  plasma transport 261–271*
Cirrhosis of liver
  alcoholic 109–111
  myofibrillar protein 683–686
  α-oxoisocaproate infusion 285–293
Cold, anorexia nervosa 677–682
Converting-enzyme inhibitor 51–56
Cor pulmonale, oedema 255–259*
Cortisol, noise stimulation 137–141
Creatine, liver cirrhosis 683–686
Crystals, urinary 17–19, 421–425, 509–514
Cyclic AMP see Adenosine 3′:5′-cyclic monophosphate
Cytoprotection, gastric mucosa 343–348*
Dark adaptation, chronic liver disease 109–111
Dead space, atropine 549–551
Deoxycholic acid, myotonic muscular dystrophy 627–642
Deoxycorticosterone acetate–salt hypertension, vasopressin 143–149
Deoxyribonucleic acid
  liver synthesis 295–297
  muscle 83–91
Diabetes mellitus
  β-adrenoceptor blockade 131–136
  insulin biosynthesis 449–455*
Dialysis, peritoneal continuous ambulatory 479–488
1,25-Dihydroxycholecalciferol, renal function 427–429, 503–508
2,3-Diphosphoglycerate, erythrocyte metabolism 479–488
Diuresis
  glycoprotein excretion 21–26
  saralasin 573–579
Diuretics, urine osmolality in oedema 235–238
DOCA-salt hypertension, vasopressin 143–149
Dopamine
  excretion in women 209–213
  kidney 439–448*
Dual-photon absorptiometry, bone mineral content 329–336
Dyspnoea, breathing resistance 367–372
Elastase, pancreatic 321–328
Emphysema, vagotomy 311–319
Enzyme induction 521–528
Erythrocyte
  membrane cholesterol 101–107
  metabolism 479–488
  sodium efflux 101–107
  sodium transport 489–494
Essential hypertension, inheritance 151–155
Exercise
  aldosterone 595–604
  electrolyte balance 595–604
  fluid homeostasis 595–604
  isometric, hypertension 307–309
  vagotomy in emphysema 311–319
Extracellular fluid volume 43–49, 595–604
Ferritin, iron overload 529–540
Fibrin, renal blood flow 35–41
Fibroblast, skin, \( \alpha-L \)-iduronidase 193–201
Fibronectin, plasma and synovial fluid 71–76
Frusemide
  erythrocyte sodium efflux 101–107
  urine osmolality in oedema 235–238
Gastric inhibitory peptide, bile salt 651–659
Gastric mucosa, protection 343–348*
Gastrin, bile salt 651–659
Genetic marker, essential hypertension 151–155
Gilbert's syndrome, bile pigments 643–649
\( \beta \)-Globulins, platelet function 239–242
Gluconolactonisation rate, saralasin 573–579
Glucocorticoids, renal conversion of thyrxine 215–220
Glucose
  \( \beta \)-adrenoreceptor blockade 131–136
  insulin biosynthesis 449–455*
  kinetics 553–556
  renal tubular absorption 667–676
Glucuronosyltransferase activity, biliary bilirubin 521–528
Glutamine, metabolism 299–305
Glutathione, liver concentration 279–283
Glycerol infusion, \( \beta \)-adrenoreceptor blockade 131–136
\( [2-^{14} \text{C}] \)Glycine, bile pigment production 643–649
Glycoprotein, urinary excretion 21–26
Goldblatt hypertension 573–579
Goldblatt hypertension, indomethacin and aprotinin 361–366
Growth hormone, noise stimulation 137–141
Guanine nucleotides, dystrophic muscle 113–115
Gunn rats, heterozygous, UDP-glucuronosyltransferase 521–528
Haem biosynthesis, menstrual cycle 183–191
Haemodialysis, erythrocyte metabolism 479–488
Haemodynamics
  baroreceptor stimulation 307–309
captopril 611–615
  noise stimulation 137–141
Haemoglobin, oxygen affinity 479–488
Haemorrhage, prostaglandins and angiotensin II 169–176
Head-up tilt, subcutaneous blood flow 605–609
Heart
  aspartate aminotransferase 337–339
  beat-to-beat variation 561–562
  experimental congestive failure 465–469
Heart rate
  autonomic control 57–64
  sleep apnoea 163–167
Hepatitis, body temperature 273–277
Hepatitis, zinc deficiency and photoreceptor dysfunction 109–111
Hepatocytes, lactate uptake 411–420
Hill walking, electrolyte balance 595–604
Histamine, asthma 661–665
3-Hydroxybutyrate, obesity 77–81
18-Hydroxycorticosterone, captopril 611–615
Hypernatraemia, dietary sodium intake 471–477
Hyperparathyroidism (secondary)
  vitamin D deficiency 381–387
  X-linked hypophosphataemia 503–508
Hypertension
  blacks and whites 1–6*
  body fluid 43–49
  borderline 307–309
  DOCA-salt 143–149
dopamine 439–448*
edemiology 1–6*
Hypertension (continued)
- essential 151-155, 307-309
- ethnic differences 1-6*
- experimental 361-366, 573-579
- Goldblatt 361-366, 573-579
- isometric exercise 307-309
- mortality 1-6*
- platelet noradrenaline 151-155
- potassium 1-6*, 117
- sodium 1-6*, 117
- vasopressin 143-149
- whites and blacks 1-6*

Hyperthermia, anorexia nervosa 677-682
Hypertriglyceridaemia, C-apoproteins 125-129*
Hypertriglyceridaemia, very-low-density lipoprotein 93-100
Hypoglycaemia, β-adrenoceptor blockade 131-136
Hyponatraemia, frusemide and renal water excretion 235-238
α-L-Iduronidase, leucocytes and fibroblasts 193-201
Indomethacin
captopril 611-615
dopamine excretion 209-213
sodium chloride excretion 27-33, 209-213
Goldblatt hypertension 361-366
Inflation reflex, pulmonary, heart rate 163-167
Inheritance
- essential hypertension 151-155
- lipoprotein receptor activity 397-401
Insulin
- biosynthesis 449-455*
- Interstitial fluid volume 43-49
Intestine, small
- absorption 617-626
- hydrolysis of PABA-peptide 557-560
- muscarinic cholinergic receptors 203-207
Intracellular fluid volume 43-49
Iron
- overload 529-540
- uptake 529-540
Ischaemic heart disease 119-123*
Isoenzyme subforms, aspartate aminotransferase 337-339
Isoferritins, iron overload 529-540
Isometric exercise, hypertension 307-309
Jaundice
- erythrocyte membrane permeability 101-107
- renal function 431-433
Kallikrein, Goldblatt hypertension 361-366
Ketones, obesity 77-81
6-Keto-prostaglandin E, and F1α, platelet aggregation 177-181
Kidney
- acute failure 35-41
- albuminurka 495-502
- bile acids 431-433
- blood flow 169-176, 255-259*, 573-579
- chronic failure 479-488, 489-494, 561-562
denervation 457-464
1,25-dihydroxycholecalciferol 427-429
dopamine 439-448*
haemodynamics 457-464
indomethacin 27-33
β2-microglobulin catabolism 403-410
renin 157-162
thyroxine deiodination 215-220
vascular resistance 573-579
Kidney, parathyroid hormone in vitamin D deficiency 381-387
Kidney, tubular absorption
bicarbonate 667-676
calcium 503-508
glucose 667-676
Kinetics, urea, glucose and alanine 553-556
Lactate, hepatocyte uptake 411-420
Lactate infusion, β-adrenoceptor blockade 131-136
Leucine, metabolism in cirrhosis 285-293
Leucocyte
- δ-aminolaevulinic acid synthase 183-191
- α-L-iduronidase 193-201
- sodium transport 563-564
Lipids, membrane 101-107
Lipoprotein lipase, 93-100
Lipoproteins
- cholesterol transport 261-271*
- high density 125-129*
- hypertriglyceridaemia 93-100
- low-density 397-401
- receptor activity 397-401
- very-low density 93-100, 125-129*
Liver
- body temperature and vascular exclusion 273-277
glutathione 279-283
Liver damage
- experimental 65-70
- regeneration 295-297
Liver disease
- alcoholic cirrhosis 109-111
- cirrhosis 109-111, 285-293, 683-686
- experimental 65-70
- photoreceptor dysfunction 109-111
- zinc deficiency 109-111
Load detection, breathing 367-372
Lumbar spine, osteoporosis bone mineral 329-336
Lung, alveolar gas mixing efficiency 541-547
Subject Index

α₂-Macroglobulin, combination with elastase 321–328
Magnesium, urinary 17–19
Mast cell mediators 661–665
Meclofenamate, blood flow regulation 169–176
Menstrual cycle, haem biosynthesis 183–191
Metabolism, brain 567–572*
3-Methylhistidine, liver cirrhosis 683–686
β₂-Microglobulin, plasma protein binding 403–410
Microspheres, renal blood flow 35–41
Mineralocorticoids, salt retention in bile-duct ligation 65–70
Mononuclear cells, low-density lipoprotein receptor activity 397–401
Motilin, bile salt 651–659
Mucociliary transport 13–16
Mucus–bicarbonate barrier 343–348*
Muscarinic cholinergic receptors, intestinal and pancreatic 203–207
Muscle chemistry, undernutrition and sepsis 83–91
Muscle fibres, knee injury 227–234
Muscle protein, liver cirrhosis 683–686
Muscular dystrophy, purine nucleotide profile 113–115
Myeloma, apolipoprotein C-II deficiency 93–100
Myocardial infarction 119–123*, 243–245
Myotonic dystrophy, abnormal bile acids 627–642
Nasal mucosa, mucociliary transport 13–16
Natriuresis, saralasin 573–579
Neck chamber 581–588
Needle biopsy, muscle 83–91
Negative pressure, lower body 51–56
Neostigmine, baroreflex responsiveness 581–588
Nephrotoxicity, bile acids 431–433
Neuromuscular disease, thoracoabdominal movements 7–11*
Neutron activation analysis, calcium 389–396
Nitrogen metabolism
- glutamine 299–305
- α-oxoisocaproate 285–293
- Nitrogen washout, alveolar gas mixing 541–547, 549–551
Noise, blood pressure and stress hormones 137–141
Noradrenaline
- congestive heart failure 465–469
- noise stimulation 137–141
- plasma kinetics 247–254*
- platelet release 151–155
Nutrition, muscle intracellular amino acids 85–91
Obesity, fasting and alanine and 3-hydroxybutyrate 77–81
(±)-Octanoylcarnitine, hepatic deoxyribonucleic acid synthesis 295–297
Oedema
- congestive heart failure 465–469
- cor pulmonale 255–259*
- diuretics and renal water excretion 235–238
- exercise 595–604
Osteomalacia, secondary hyperparathyroidism 381–387
Osteoporosis
- bone mineral content 329–336
- calcium balance and sex hormones 221–226
- parathyroid hormone 389–396
- α-Oxoisocaproate, amino acid and nitrogen metabolism 285–293
PABA-peptide, intestinal non-pancreatic hydrolysis 557–560
Pancreas, muscarinic cholinergic receptors 203–207
Pancreatic elastase, acute pancreatitis 321–328
Pancreatic function
- duodenal bile salt 651–659
- PABA-peptide hydrolase 557–560
- pancreatic polypeptide, bile salt 651–659
- Pancreatitis, plasma elastase 321–328
- Parasympathetic nervous system, small intestine and pancreas 203–207
Parathyroid hormone
- kidney and vitamin D deficiency 381–387
- osteoporosis 389–396
Peptides, intestinal absorption 617–626
pH
- distal tubule 667–676
- hepatocyte lactate uptake 411–420
Phenylephrine, baroreceptor sensitivity 581–588
Phosphataemia, renal tubular absorption 503–508
Phosphate, X-linked hypophosphataemia 503–508
Photoreceptor dysfunction, chronic liver disease 109–111
Plasma membrane, lactate uptake 411–420
Plasma renin activity
- active renin 435–437
- hypertension 1–6*, 43–49
- intravascular coagulation 35–41
- renal failure 667–676
Plasma volume 43–49, 595–604
Platelets
- adhesiveness 239–242
- aggregation 177–181, 239–242
- noradrenaline in hypertension 151–155
Porphyria, haem biosynthesis and menstrual cycle 183–191

Posture

- heart rate 57–64
- subcutaneous blood flow 605–609

Potassium

- aldosterone 373–380
- excretion 471–477
- hypertension 1–6*, 117

Proctolin, noise stimulation 137–141

Propranolol

- baroreflex responsiveness 581–588
- diabetic subjects 131–136

Prostacyclin, platelet anti-aggregatory activity 177–181

Prostaglandin E, urinary excretion 27–33

Prostaglandins

- blood flow regulation 169–176
- captopril 611–615
- cytoprotection 343–348*
- dopamine excretion 209–213
- gastric mucosa 343–348*
- Goldblatt hypertension 361–366
- platelet aggregation 239–242

Proteins

- plasma 403–410
- muscle 683–686
- turnover 299–305, 403–410

Proteinuria, experimental 495–502

Pulmonary vascular resistance, cor pulmonale 255–259*

Purine nucleotides, muscular dystrophy 113–117

Radioimmunoassay

- angiotensinogen 355–360
- 1,25-dihydroxycholecalciferol 427–429

Receptors, lipoprotein, blood mononuclear cells 397–401

Renal failure

- acute 35–41
- chronic 479–488, 489–494

Renal tubules

- absorption 503–508, 667–676
- deiodination of thyroxine 215–220

Renin

- congestive heart failure 465–469
- dopamine 439–448*
- exercise 595–604
- inactive 435–437
- low-renin hypertension 1–6*
- renal molecular-weight conversion 157–162
- thrombin 35–41

Renin–angiotensin system

- intravascular coagulation 35–41
- sympathetic reflexes 51–56

Renin-binding substance, kidney 157–162

Rheumatoid arthritis, fibronectin 71–76

R--R interval, posture 57–64

Saralasin, renal function 573–579

Secretin, bile salt 651–659

Sepsis, muscle intracellular amino acids 83–91

Sex hormones, calcium balance in osteoporosis 221–226

Signal Detection Theory, breathing 367–372

Single breath test, alveolar gas mixing 541–547

Skin blood flow

- subatmospheric pressure 605–609

Sleep apnoea, heart rate 163–167

Sodium

- aldosterone 373–380
- balance 595–604
- bile-duct ligation 65–70
- dopamine 439–448*
- erythrocyte permeability 101–107
- hypertension 1–6*, 117
- hyponatraemia 235–238
- prostaglandins 27–33
- transport 489–494

Sodium chloride excretion

- blood volume expansion 457–464
- dietary sodium 471–477
- indomethacin 209–213
- prostaglandins 27–33

Sodium chloride loading

- hypernatraemia 471–477
- renal blood flow 35–41
- tubular function 667–676

Sodium taurocholate, duodenal perfusion 651–659

Sodium urate, calcium oxalate crystal growth 509–515

Spine, osteoporosis bone mineral 329–336

Spleen, blood flow 169–176

Stomach, mucosal protection 343–348*

Stress

- hypertension 1–6*
- noise 137–141

Stress hormones, noise stimulation 137–141

Subatmospheric pressure

- lower body 51–56
- skin blood flow 243–245

Substrate specificity, α-Liduronidase 193–201

Sulphydryl groups, molecular-weight conversion of renin 157–162

Sympathetic nervous system

- angiotensin 51–56
- assessment of function 247–254*
- noradrenaline plasma kinetics 247–254*
- vascular reflexes 51–56, 605–609

Synovial fluid, fibronectin 71–76
<table>
<thead>
<tr>
<th>Subject Index</th>
<th>xiii</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tamm–Horsfall glycoprotein, urinary excretion</td>
<td>21–26</td>
</tr>
<tr>
<td>Tetraplegia, subcutaneous blood flow</td>
<td>605–609</td>
</tr>
<tr>
<td>Thermoregulation, anorexia nervosa</td>
<td>677–682</td>
</tr>
<tr>
<td>Thiol groups, molecular-weight conversion of renin</td>
<td>157–162</td>
</tr>
<tr>
<td>Thoracoabdominal movements, breathing</td>
<td>7–11*</td>
</tr>
<tr>
<td>Thyroxine, glucocorticoids and renal deiodination</td>
<td>215–220</td>
</tr>
<tr>
<td>Tidal volume, thoracoabdominal movements</td>
<td>7–11*</td>
</tr>
<tr>
<td>Tomography, cerebral blood flow</td>
<td>567–572*</td>
</tr>
<tr>
<td>Transport</td>
<td>489–494</td>
</tr>
<tr>
<td>erythrocyte sodium</td>
<td>489–494</td>
</tr>
<tr>
<td>hepatocyte lactate uptake</td>
<td>411–420</td>
</tr>
<tr>
<td>plasma cholesterol</td>
<td>261–271*</td>
</tr>
<tr>
<td>polymorphonuclear leucocytes</td>
<td>563–564</td>
</tr>
<tr>
<td>renal</td>
<td>503–508</td>
</tr>
<tr>
<td>sodium</td>
<td>563–564</td>
</tr>
<tr>
<td>Transporters, hepatocyte lactate uptake</td>
<td>411–420</td>
</tr>
<tr>
<td>Triglyceride-rich lipoproteins, metabolism</td>
<td>125–129*</td>
</tr>
<tr>
<td>3,5,3'-Tri-iodothyronine, glucocorticoids and renal formation</td>
<td>215–220</td>
</tr>
<tr>
<td>Trypsin, bile salt</td>
<td>651–659</td>
</tr>
<tr>
<td>Twins, heritability of lipoprotein receptor activity</td>
<td>397–401</td>
</tr>
<tr>
<td>Ultrasonography, quadriceps femoris</td>
<td>227–234</td>
</tr>
<tr>
<td>Uraemia, oral</td>
<td>1,25-dihydroxycholecalciferol</td>
</tr>
<tr>
<td>Urate, urinary calcium oxalate</td>
<td>421–425, 509–514</td>
</tr>
<tr>
<td>Urea, kinetics and glucose</td>
<td>553–556</td>
</tr>
<tr>
<td>Uric acid, calcium oxalate crystal growth</td>
<td>509–514</td>
</tr>
<tr>
<td>Urine</td>
<td>495–502</td>
</tr>
<tr>
<td>albumin</td>
<td>495–502</td>
</tr>
<tr>
<td>calcium oxalate</td>
<td>17–19, 421–425, 509–514</td>
</tr>
<tr>
<td>crystal formation</td>
<td>17–19, 421–425</td>
</tr>
<tr>
<td>glycoprotein</td>
<td>21–26</td>
</tr>
<tr>
<td>macromolecules</td>
<td>509–514</td>
</tr>
<tr>
<td>oxalate</td>
<td>17–19, 421–425</td>
</tr>
<tr>
<td>Ursodeoxycholic acid, myotonic dystrophy</td>
<td>627–642</td>
</tr>
<tr>
<td>Vagotomy</td>
<td>311–319</td>
</tr>
<tr>
<td>breathing and exercise ability</td>
<td>311–319</td>
</tr>
<tr>
<td>muscarinic cholinergic receptors of intestine and pancreas</td>
<td>203–207</td>
</tr>
<tr>
<td>Vagus nerve, sleep apnoea and heart rate</td>
<td>163–167</td>
</tr>
<tr>
<td>Vascular resistance, renal</td>
<td>573–579</td>
</tr>
<tr>
<td>Vasoconstriction</td>
<td>565–566</td>
</tr>
<tr>
<td>captopril inhibition</td>
<td>565–566</td>
</tr>
<tr>
<td>posture in tetraplegia</td>
<td>605–609</td>
</tr>
<tr>
<td>sympathetic reflex</td>
<td>51–56</td>
</tr>
<tr>
<td>Vasopressin, angiotensin</td>
<td>143–149, 341–342</td>
</tr>
<tr>
<td>Veno-arteriolar reflex</td>
<td>203–207</td>
</tr>
<tr>
<td>myocardial infarction</td>
<td>243–245</td>
</tr>
<tr>
<td>posture in tetraplegia</td>
<td>605–609</td>
</tr>
<tr>
<td>Ventilation, distribution</td>
<td>549–551</td>
</tr>
<tr>
<td>Vitamin D deficiency, secondary hyperparathyroidism</td>
<td>381–387</td>
</tr>
<tr>
<td>Volume expansion, renal denervation</td>
<td>457–464</td>
</tr>
<tr>
<td>von Willebrand factor, physiological inhibition</td>
<td>239–242</td>
</tr>
<tr>
<td>Water, total body</td>
<td>43–49</td>
</tr>
<tr>
<td>Zinc deficiency, chronic liver disease</td>
<td>109–111</td>
</tr>
</tbody>
</table>